Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Alpelisib Plus Fulvestrant in PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer After a CDK4/6 Inhibitor (BYLieve): One Cohort of a Phase 2, Multicentre, Open-Label, Non-Comparative StudyLancet Oncol 2021 Apr 01;22(4)489-498, HS Rugo, F Lerebours, E Ciruelos, P Drullinsky, M Ruiz-Borrego, P Neven, YH Park, A Prat, T Bachelot, D Juric, N Turner, N Sophos, JP Zarate, C Arce, YM Shen, S Turner, H Kanakamedala, WC Hsu, S Chia
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.